Efficacy and safety of oxum in treatment of chronic wounds.

Chronic wounds represent a major health burden contributing to substantial mortality, morbidity and costs. Several new treatment options are currently available, which has revolutionised the management of chronic wounds. The present study is a single centre, prospective, clinical trial comparing oxum (super oxidised water) and betadine as a topical treatment of chronic wounds conducted in 30 Indian patients, with 15 patients in each group. At the end of the study, there was a significant reduction in primary parameters such as wound area and microbial colony count in oxum treated group compared to betadine group. However, both the oxum and betadine treated group showed a similar results when the secondary parameters such as oedema, erythema and granulation tissue were considered. Oxum was better tolerated than betadine. It can be concluded that use of oxum (super oxidised water) is a novel technological innovation in the therapy of chronic wounds. Oxum has been shown to be effective, well tolerated and superior to betadine in wound care.

Efficacy and safety of oxum in treatment of the venous ulcer.

The present study was carried out to find out the efficacy and safety of oxum in the treatment of venous ulcers. The oxum (superoxidised water) is a pH neutral, non-irritating, aqueous solution that possesses a good antiseptic, antimicrobial activity and wound healing properties. The study was conducted in 30 patients of venous ulcers with a culture examination positive for pathogenic microbial flora. All patients received a gauze dressing impregnated with oxum followed by compression bandage for 28 days. The primary endpoint was the calculation of ulcer size using ulcer tracing. Assessment of periwound oedema, periwound erythema, wound fibrin and wound granulations were considered as secondary endpoints. There was a singificant reduction in ulcer size starting from day 7 of the treatment. Significant improvements in secondary endpoints were observed. This study has demonstrated that oxum improved the clinical status, reduced the signs of inflammation in venous ulcers in addition to its well confirmed anti-infective properties.

Itopride and pantoprazole outcomes in diabetic gastroparesis trial (IPOD trial).

The most common cause of gastroparesis is diabetes mellitus. The present study was carried out to asses the combination of itopride and pantoprazole in the treatment of diabetic gastroparesis. The study was an open label, multicentre, conducted in 743 patients with diabetic gastroparesis for a period of 3 weeks. The efficacy parameters included nausea, vomiting, early satiety, bloating, postprandial fullness, epigastric pain and regurgitation. The patients were evaluated based on the frequency and severity of symptoms and compared with the baseline scores. There were significant improvement in severity as well as the frequency of all the symptom parameters of the disease (p<0.001). The physicians' evaluation to the therapy was rated either excellent or good.

Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.

The present study was carried out to evaluate the sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime. Samples were collected from clinical specimens and micro-organisms were isolated from clinical specimens. Strains of micro-organisms isolated from clinical specimens were identified using standard methods like morphology, colony characteristics and biochemical reactions. Sensitivity was carried out using Kirby Bauer disc diffusion method. Minimum inhibitory concentrations (MICs) for all the antibiotics were carried out as per guideline of Clinical and Laboratory Standard Institute (CLSI). The results of the study demonstrated that cefepime and tazobactum exhibits good activity against Gram +ve and Gram-ve organisms.